...
首页> 外文期刊>BMC Neurology >Identification of VPS35 p.D620N mutation-related Parkinson’s disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review
【24h】

Identification of VPS35 p.D620N mutation-related Parkinson’s disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review

机译:在成功的双侧丘脑底深核刺激的台湾家庭中鉴定与VPS35 p.D620N突变相关的帕金森氏病:一例病例并文献复习

获取原文
           

摘要

Vacuolar protein sorting 35 (VPS35) was recently reported to be a genetic cause for late-onset autosomal dominant Parkinson’s disease (PD). However, VPS35 mutations are rarely reported in Asian populations. Herein, we report the first Taiwanese family with the pathogenic VPS35 p.D620N mutation, including one patient treated successfully with subthalamic nucleus deep brain stimulation (STN-DBS). A 61-year-old woman presented with progressive left hand resting tremor at the age of 42. Neurological examinations revealed mask face and akinetic-rigidity over left extremities. She showed a good response to levodopa treatment, and her unified Parkinson’s disease rating scale (UPDRS) motor scores improved from 42 to 15 under the levodopa equivalent dose of 1435?mg/day. She developed peak-dose dyskinesia and motor fluctuation seven years after the onset of symptoms, and received bilateral STN-DBS at the age of 55. Stimulation led to a marked improvement in her motor symptoms with a 37% improvement in the UPDRS motor score during the OFF period five years after surgery. The patient’s mother and three siblings were also diagnosed with PD in their forties, following an autosomal-dominant inheritance pattern. We performed genetic analysis of the proband using a targeted next generation sequencing (NGS) panel covering 17 known PD-causative genes. We identified a pathogenic missense mutation in VPS35 gene, c.1858G?>?A (p.D620N), in this patient. This is the first report of the VPS35 p.D620N mutation in a Taiwanese family. Additionally, our report contributes to the current understanding of genetically defined PD patients treated successfully with STN-DBS.
机译:最近报道了液泡蛋白分选35(VPS35)是迟发性常染色体显性帕金森氏病(PD)的遗传原因。但是,在亚洲人群中很少报道VPS35突变。在此,我们报告了台湾第一个具有致病性VPS35 p.D620N突变的家庭,其中包括一名成功用丘脑底核深部脑刺激(STN-DBS)治疗的患者。一名61岁的女性在42岁时出现进行性左手休息性震颤。神经系统检查显示左四肢的面罩脸和运动僵硬。她对左旋多巴的治疗表现出良好的反应,在1435?mg /天的左旋多巴等效剂量下,她的统一帕金森氏疾病评级量表(UPDRS)运动评分从42提高到15。症状发作后七年,她出现了高峰剂量的运动障碍和运动障碍,并在55岁时接受了双侧STN-DBS。刺激导致她的运动症状显着改善,在此期间,UPDRS运动评分提高了37%。手术后五年的关闭期。按照常染色体显性遗传模式,患者的母亲和三个兄弟姐妹四十多岁也被诊断出患有PD。我们使用覆盖17个已知PD致病基因的靶向下一代测序(NGS)面板对先证者进行了遗传分析。我们在该患者中发现了VPS35基因的致病性错义突变,c.1858Gβ>ΔA(p.D620N)。这是台湾家庭中VPS35 p.D620N突变的首次报道。此外,我们的报告有助于对成功用STN-DBS治疗的遗传定义的PD患者的当前了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号